Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands

Details Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands

C - Chemistry, Metallurgy

07

D

C07D 209/08 (2006.01) A61K 31/40 (2006.01) C07D 401/04 (2006.01) C07D 401/12 (2006.01) C07D 409/04 (2006.01) C07D 409/12 (2006.01)

Patent

CA 2341525

For use in therapy a chemical compound of formula (I), wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, heterocyclyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, wherein at least one of R4 to R7 is a substituent group other than hydrogen, and pharmaceutically acceptable salts and prodrugs thereof, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and especially for the treatment of obesity; chemical compounds of formula (I) other than compounds wherein R7 is hydroxy.

L'invention concerne un composé chimique à usage thérapeutique représenté par la formule (I), dans laquelle R¿1? à R¿3? sont indépendamment choisis parmi hydrogène et alkyle; R¿4? à R¿7? sont indépendamment choisis parmi hydrogène, halogène, hydroxy, alkyle, aryle, hétérocyclyle, alcoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyle, alkylsulfonyle, arylsulfoxyle, arylsulfonyle, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldéhyde, alkylcarbonyle, arylcarbonyle, aminocarbonyle, monoalkylaminocarbonyle, dialkylaminocarbonyle, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino et dialkylaminocarbonylamino, l'un des groupes R¿4? à R¿7? au moins étant un groupe substituant autre que l'hydrogène. L'invention concerne également des sels et des promédicaments pharmaceutiquement acceptables de ce composé, destiné notamment au traitement des troubles du système nerveux central; des lésions du système nerveux central; des troubles cardio-vasculaires; des troubles gastro-intestinaux; du diabète insipide; et de l'apnée du sommeil; et plus particulièrement au traitement de l'obésité. L'invention concerne enfin des composés de formule (I) autres que les composés où R¿7? désigne un hydroxy.

Affiliated with

Also associated with

Rating

Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1849734